Sponsored Links
| Protalix BioTherapeutics Receives PDUFA Date For Taliglucerase Alfa |
 |
 |
 |
| Medical News - Lymphology and Lymphedema | |||
|
Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011... Read more: Lymphology/Lymphedema News From Medical News Today
|